AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04279015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape procedure
Description: Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application.
Study NCT05599997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 30 mg, immediate release tablet, single dose, oral
Study NCT05599997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecavaptan (BAY1753011)
Description: 15 mg, immediate release tablet, single dose, oral
Study NCT04476888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP)
Description: 500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.
Study NCT04476888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Drugs and supportive care
Description: This will include drugs like steroids, tocilizumab, azithromycin and supportive care
Study NCT04476888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drugs and supportive care
Description: This will include drugs like steroids, tocilizumab, azithromycin and supportive care
Study NCT04375774 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FFP2
Description: Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
Study NCT04375774 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Facial mask
Description: Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
Study NCT04375774 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MFS
Description: Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
Study NCT05853770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TGfU volleyball intervention
Description: Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min).
Study NCT05853770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular physical education classes
Description: Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
Study NCT01866254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Injection of 200 mcg of intrathecal morphine
Study NCT03092232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
Study NCT03092232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
Study NCT03092232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
Study NCT03092232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.
Study NCT02953691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galacto-Oligosaccharide
Description: Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
Study NCT02953691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
Study NCT00683137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
Study NCT00683137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
Study NCT00683137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib/placebo
Description: valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
Study NCT00976027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine High Dose
Description: 0.5 mL, Intramuscular
Study NCT00976027 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT02659735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
Study NCT02659735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
Study NCT02659735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
Study NCT02659735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
Study NCT01470170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Give Alfentanil before TCI Propofol sedative bronchoscope
Study NCT01470170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Study NCT00133003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: 0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
Study NCT00133003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
Study NCT04122469 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
Study NCT01145586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactase Oral Tablets
Description: 3 tablets/day for 42 days Take with breakfast, lunch and dinner
Study NCT01145586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactase Oral Tablets
Description: 3 tablets/day for 42 days Take with breakfast, lunch and dinner
Study NCT02423369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral near infrared spectroscopy
Description: At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
Study NCT02423369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-100B protein in serum
Description: 0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
Study NCT02423369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSE protein in serum
Description: 0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
Study NCT00221468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
Study NCT04748367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Virtual Reality Headset running SILVER software
Study NCT01623557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-MVA CS
Description: 1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.
Study NCT01623557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63-MVA ME-TRAP
Description: 1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.
Study NCT01623557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection Administered by Mosquito Bite
Description: Approximately 3 weeks post MVA dosing
Study NCT00771953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricoxib
Description: Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
Study NCT00771953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
Study NCT00771953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel or Pemetrexed
Description: Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
Study NCT00771953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel or Pemetrexed
Description: Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
Study NCT02933684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seromycin
Description: Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
Study NCT03712579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA-Rich Meal
Description: Saturated fatty acid-rich test meal, containing 75g test fat
Study NCT03712579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA-Rich Meal
Description: Monounsaturated fatty acid-rich test meal, containing 75g test fat
Study NCT04593069 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive assessment
Description: 6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
Study NCT03993366 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fiasp+Pramlintide Closed-Loop System
Description: Closed-loop insulin delivery with Fiasp insulin and pramlintide
Study NCT03993366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp Closed-Loop System
Description: Closed-loop insulin delivery with Fiasp insulin alone
Study NCT03198208 — intervention group
Intervention type: DRUG
Intervention: Fentanyl dose administration
Study NCT02989519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dydrogesterone
Study NCT02933684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
Study NCT02933684 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
Study NCT02933684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in pill form.
Study NCT04655794 — intervention group
Intervention type: DRUG
Intervention: 3HP
Description: all patients taking 3HP under directly observed preventive therapy (DOPT) program
Study NCT01051154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid (DHA)
Description: Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
Study NCT01051154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
Study NCT01919281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Study NCT01919281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training
Study NCT00635258 — intervention group
Intervention type: DRUG
Intervention: triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)
Description: 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
Study NCT00635258 — intervention group
Intervention type: DRUG
Intervention: GnRH antagonist (Orgalutran®)
Description: GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
Study NCT05423561 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: exchange nailing with larger, thicker nail crossing corticalization
Description: exchange nailing with larger, thicker nail crossing corticalization
Study NCT04986761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of implant single crown
Description: Digital or Conventional Workflows for treatment of implant single crown and materials used.
Study NCT01521312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 5mg a day for 11-14 weeks
Study NCT01521312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: one tablet a day for 11-14 weeks
Study NCT00006205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron + cognitive behavioral therapy
Description: ondansetron (4 mcg/kg b.i.d)
Study NCT00006205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate + cognitive behavioral therapy
Description: topiramate (up to 300 mg/day)
Study NCT00006205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + cognitive behavioral therapy
Description: placebo
Study NCT00006205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron + topiramate + cognitive behavioral therapy
Description: ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
Study NCT03061006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: 150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
Study NCT03061006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
Study NCT03238690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Controlled Cardiac Reloading through LVAD Speed Adjustment
Description: LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
Study NCT04079309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lavender/Orange
Description: A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
Study NCT04551872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital weight loss intervention
Description: Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
Study NCT00635219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules; daily; orally
Study NCT00635219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 2.5 mg/day; encapsulated tablets; orally
Study NCT00635219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 5 mg/day; encapsulated tablets; orally
Study NCT00635219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 10 mg/day; encapsulated tablets; orally
Study NCT00635219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: 60 mg/day; encapsulated capsules; orally
Study NCT02133690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)
Description: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
Study NCT02133690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
Study NCT00984997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Segmentectomy or lobectomy with en bloc resection of the involved chest.
Study NCT00984997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest Irradiation
Description: Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
Study NCT00984997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
Study NCT00984997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
Study NCT00984997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
Study NCT01755000 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: USCOM scan
Study NCT01755000 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fluid Bolus
Study NCT02961738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Description: Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
Study NCT02961738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Analytic Therapy (CAT)
Description: Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relationship Enhancement (MBRE)
Description: Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: Participants and partner receive self-help materials.